Last updated: February 8, 2026
Case Overview
ACADIA Pharmaceuticals Inc. filed a patent infringement lawsuit against Aurobindo Pharma Limited on July 13, 2020, in the District of Delaware. The complaint alleges that Aurobindo infringed ACADIA's patents related to methods of treating schizophrenia using proprietary formulations of cariprazine, a dopamine D3/D2 receptor partial agonist.
Legal Claims and Patent Defense
ACADIA asserts infringement of U.S. Patent Nos. 10,675,043 and 10,768,779. The patents cover specific formulations of cariprazine, including dosage ranges, methods of treatment, and pharmaceutical composition claims. Aurobindo disputes the validity of these patents, asserting non-infringement and seeking to challenge their validity through defenses and counterclaims.
Key Patent Details
| Patent Number |
Issue Date |
Expiration Date |
Claims Focus |
| 10,675,043 |
June 23, 2020 |
June 2035 |
Formulations and methods of treating schizophrenia with specific doses of cariprazine. |
| 10,768,779 |
September 8, 2020 |
June 2035 |
Similar scope, emphasizing pharmaceutical compositions optimized for patient treatment. |
Procedural Timeline
- July 2020: Complaint filed.
- August 2020: Aurobindo files motion to dismiss for failure to state a claim and lack of patent validity.
- October 2020: Court denies in part, grants in part motion, allowing certain claims to proceed.
- December 2020 – Present: Discovery phase, with document exchanges and depositions.
Litigation Dynamics
ACADIA pursues an assertion of patent rights based on prior research and proprietary formulations. Aurobindo questions the novelty and non-obviousness of the patents, arguing that similar formulations and treatment methods were known prior to the patent filings, thereby seeking invalidity under 35 U.S.C. §102 and §103.
The case also involves a potential stay or transfer to the Patent Trial and Appeal Board (PTAB) for inter partes review (IPR). Aurobindo has filed for IPR on one of the patents, which could impact the litigation timeline and outcomes.
Potential Implications
- Market Impact: If Aurobindo’s generic products enter the market prior to patent expiration, ACADIA’s revenue from cariprazine could decline significantly.
- Legal Strategy: ACADIA aims to enforce its patent rights to delay generic entry, with ongoing validation of the patents' strength through infringement and validity battles.
- Patent Lifecycle: The enforcement aligns with the remaining patent life until approximately 2035, allowing ACADIA to maintain market exclusivity for another decade.
Patent Validity and Challenges
Aurobindo’s IPR petition targets key claims related to formulations and methods, arguing obviousness over prior art references. The outcome of the IPR proceedings could lead to patent cancellations or reaffirmation, significantly influencing the district court case.
Current Status
As of March 2023, the case remains unresolved. The district court is reviewing the validity contentions, while the PTAB’s decisions on the IPR are pending.
Strategic Considerations
- Defense hinges on establishing the patents’ non-obviousness and discovery of evidence that confirms the uniqueness of ACADIA's formulations.
- Aurobindo may leverage IPR outcomes to invalidate key patent claims, weakening ACADIA’s infringement claims.
- Settlements or licensing agreements could emerge if patent validity is upheld and infringement is established.
Key Takeaways
- The litigation emphasizes the importance of patent strength in maintaining exclusivity for pharmaceutical formulations.
- Aurobindo's challenge through IPR could substantially influence the case outcome.
- The case illustrates the ongoing industry trend where generic companies challenge patents to accelerate market entry.
- Patent validity remains central; court and PTAB rulings will shape future competitive dynamics.
- ACADIA’s patent portfolio for cariprazine remains a critical asset supporting revenue through 2035.
FAQs
1. What are the main patents involved in the case?
The case involves U.S. Patent Nos. 10,675,043 and 10,768,779, which cover formulations and methods for treating schizophrenia with cariprazine.
2. What is Aurobindo's primary legal argument?
Aurobindo claims the patents are invalid due to lack of novelty and obviousness based on prior art references.
3. How could the outcome of IPR affect the litigation?
If the PTAB cancels key claims, ACADIA’s infringement case weakens, possibly leading to settlement or dismissal. Valid patents reinforce ACADIA’s legal position.
4. What is the potential commercial impact of this case?
A ruling in favor of ACADIA could delay generic competition until patent expiration around 2035. An invalidation could allow quicker market entry for generics.
5. When is the expected resolution?
No definitive timeline; IPR decisions are expected within 12-18 months of filing. District court rulings could extend over multiple years.
References
- United States Patent and Trademark Office (USPTO). Patent documents for US 10,675,043 and US 10,768,779.
- District of Delaware Court records, case 1:20-cv-00985-RGA.
- Aurobindo’s IPR filings and patent challenge documents.
- Industry analysis reports on pharmaceutical patent litigation trends (e.g., [1]).
[1] Bloomberg Industry Reports, 2022.
